International Journal of Clinical Research

Multiple myeloma (MM) is a malignant tumor originating from bone marrow plasma cells, characterized by abnormal proliferation of plasma cells accompanied by the production of monoclonal immunoglobulins. At present, the treatment of multiple myeloma mainly includes chemotherapy, immunotherapy, stem cell transplantation and other methods. Interleukin-2 (IL-2), as an important immunomodulator, has shown potential application value in the treatment of various malignant tumors. In the treatment of MM patients, IL-2 effectively inhibits the growth and spread of tumor cells by enhancing the activity of immune cells such as T cells and natural killer cells, thereby improving the prognosis of MM patients. This article retrospectively analyzed the clinical data of 2 patients with multiple myeloma to explore the effect of interleukin-2 adjuvant therapy on patients with multiple myeloma, in order to provide new ideas and methods for the treatment of multiple myeloma.

Multiple myeloma; Chemotherapy; Interleukin-2; Adjuvant therapy; Adverse reactions